VF
AIMT

Virtu Financial’s Aimmune Therapeutics AIMT Stock Holding History

Virtu Financial’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-9,166
Closed -$246K – 2442
2018
Q2 		$246K Buy
+9,166
New +$281K 0.01% 1333
2018
Q1 		– Sell
-6,316
Closed -$239K – 2896
2017
Q4 		$239K Buy
+6,316
New +$204K 0.01% 1489

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Virtu Financial's AIMT Position: Q3 2018 in Review

Virtu Financial sold out of Aimmune Therapeutics (AIMT) in Q3 2018, closing a stake of 9,166 shares — an estimated $246K sold.

Virtu Financial first reported a position in AIMT in Q4 2017 and held it in 2 quarters. The position peaked at $246K in Q2 2018. 142 funds tracked by Wall St. Rank hold AIMT as of Q3 2018.

  • Virtu Financial reported no remaining Aimmune Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Virtu Financial sold 9,166 Aimmune Therapeutics shares in Q3 2018, an estimated $246K.
  • Virtu Financial first reported a position in Aimmune Therapeutics in Q4 2017 and held it in 2 quarters.
  • Virtu Financial's Aimmune Therapeutics position peaked at $246K in Q2 2018.
  • 142 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2018.

Based on Virtu Financial's 13F filing for Q3 2018, filed 13 Nov 2018.